Daiichi Sankyo has entered into an exclusive licence agreement worth up to $300m with Alteogen to develop a subcutaneous ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

Merck’s stock fell Thursday morning, despite the company beating profit and sales estimates for the third quarter.

Total Worldwide Sales Were $16.7 Billion, an Increase of 4% From Third Quarter 2023; Excluding the Impact of Foreign Exchange ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...

While the Dow Jones Industrial Average has reached all-time highs recently, one of its newest members, Merck, traded briefly Thursday morning at a 52-week low.

Outlook Reflects a Net Negative Impact of $0.24 per Share Related to Business Development Transactions With Curon Biopharmaceutical and Daiichi Sankyo Merck (NYSE: MRK), known as MSD outside the ...

Merck & Co. Inc.’s stock swung between gains and losses premarket Thursday, after the drug company beat profit and sales estimates for the third quarter, but lowered guidance due to deals with ...

Merck & Co. Inc.'s stock fell 3% Thursday ... charges stemming from deals with partners Curon Biopharmaceutical and Daiichi Sankyo. The Rahway, N.J.-based company (MRK) posted net income of ...